Evaluation of the Prognostic Value of Ki-67 in Early Stage Breast Cancer

Abstract

he expression of Ki67 is strongly associated with tumor cell proliferation and growth, and is widely used in routine pathological investigation as a proliferation marker. There is a correlation between the ratio of Ki67‑positive malignant cells and patient survival. The Ki67 protein is well characterized at the molecular level and is extensively used as a prognostic and predictive marker for cancer diagnosis and treatment. The use of Ki67 immuno-labelling as a prognostic and predictive marker has been always an interesting topic for discussion in both the neoadjuvant and adjuvant settings. This study aims to evaluate the value of Ki67 as a prognostic factor in relation to disease free survival and other clinico-pathological factors in Egyptian females with early stage breast cancer. The study cohort consisted of patients diagnosed with early stage breast cancer between January 2011 and December 2015 in Ain Shams University Hospital clinical oncology department. Information were manually retrieved from the records of the clinical oncology department at Ain Shams university hospitals. The medical files of all patients included in this study were gathered; scientific data were properly collected, revised and analyzed.